Seattle Clinical Research Center (SCRC) is pleased to announce the addition of Nicole Ehrhardt, MD, as Co-Medical Director. Dr. Ehrhardt’s primary focus will be on leveraging her expertise in endocrinology studies, in collaboration with Rainier Clinical Research Center (RCRC), to build SCRC’s cardio-metabolic research portfolio, particularly in the areas of obesity and diabetes.

Seattle Clinical Research Center (SCRC) is proud to recognize the recent FDA approval of elinzanetant (brand name Lynkuet), developed by Bayer, for the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause.

Seattle Clinical Research Center (SCRC) is proud to share that a new treatment for migraine—Atzumi™ (dihydroergotamine) nasal powder—has been approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura in adults.

Seattle Clinical Research Center is pleased to recognize the recent FDA approval of a new non-hormonal copper intrauterine device (IUD), now officially approved for up to three years of use.

Seattle Clinical Research Center (SCRC) is thrilled to announce our upcoming move to a new location, effective April 1st, 2024. The new facility is custom-built to accommodate our expanding operations and provide an enhanced environment for conducting cutting-edge multi-specialty Phase I-IV clinical trials.

SEATTLE – The clinical research site Seattle Women’s Health, Research and Gynecology has unveiled a new brand:  Seattle Clinical Research Center (SCRC).

Seattle Clinical Research Center will be closing our Gynecology practice on August 31, 2020.  We will operate exclusively as a Clinical Research Center and none of our physicians will be providing medical care to patients outside of our research studies. 

It is our responsibility to prioritize the health of ourselves, our patients, and the rest of the community, especially those that are most vulnerable to the disease.